The Business of Awareness: How Corporate Influence Shapes the Blood Clot Narrative

IWBCA
Oct 16, 2025
6 min read

Updated: Oct 19, 2025

The public conversation about blood clots has been quietly rewritten by the pharmaceutical industry. What began as legitimate health awareness has evolved into a carefully managed marketplace of influence, where lobbying dollars, advocacy funding, and media campaigns align to protect corporate interests. Major drug manufacturers bankroll “independent” organizations, finance medical societies that write treatment standards, and use emotional storytelling to frame urgency as inevitability. The result is a narrative that resembles education but functions like marketing, defining risk through the lens of profitability and keeping control of the conversation out of patients’ hands.

The Business of Awareness

The public story about blood clots, ranging from how they happen, who is at risk, and what should be done, did not form naturally. It was engineered. The language of “awareness” has been shaped over the years by the same institutions that profit from its urgency: pharmaceutical corporations, advocacy networks reliant on corporate funding, and medical societies built on sponsorship. What appears to be public health messaging is, in many cases, strategic communication—an ecosystem designed to steer fear, funding, and treatment decisions in predictable directions.

The Pharmaceutical Elephant in the Room

The blood clot narrative isn’t driven by doctors or patients but by the pharmaceutical industry itself. PhRMA, the industry’s lobbying powerhouse, poured $340 million into lobbying in 2023, the highest of any sector in the United States. The companies it represents, which include Pfizer, Bristol Myers Squibb, Johnson & Johnson, and Bayer, control the anticoagulant market and pull in staggering profits from it. Their two flagship drugs, Eliquis and Xarelto, made over $22 billion last year. That kind of money doesn’t just buy research and development; it buys influence.

Drug makers sell medication, sure, but they also sell the story that drives demand for it. They bankroll “awareness” campaigns, underwrite “independent” research, and quietly fund patient advocacy groups that appear grassroots but are financially dependent on the same corporations they claim to watchdog. A JAMA Internal Medicine analysis found that 83% of major patient advocacy organizations receive industry funding, most without transparent disclosure. That means when a nonprofit pushes a message about recognizing “the signs of blood clots,” there’s a good chance the companies profiting from anticoagulant prescriptions are behind the curtain.

The money moves through PR agencies, think tanks, and charitable foundations designed to keep the funding trail murky. One case study makes the playbook plain: Sanofi-Aventis paid Fleishman-Hillard to launch a global blood clot “awareness” campaign just as Sanofi ramped up marketing for its anticoagulant line. The campaign didn’t sell drugs directly. It didn’t have to. It manufactured fear and urgency, the kind that sends patients to doctors asking for brand-name prescriptions by name.

This isn’t an accident. It’s a business model. Pharmaceutical lobbying has rewritten public health messaging to ensure that awareness always leads to treatment, and treatment almost always means a lifelong customer. In the blood clot conversation, science and sincerity take a backseat to sales strategy. The line between public education and corporate propaganda no longer exists.

Advocacy with Strings Attached

Patient advocacy groups are the pharmaceutical industry’s cleanest delivery system for influence. Organizations like the National Blood Clot Alliance (NBCA), North American Thrombosis Forum (NATF), Thrombosis UK, and the American Blood Clot Association frame themselves as independent champions of awareness and prevention. But financial disclosures and tax filings tell a different story. Many of these same groups accept corporate sponsorships, research grants, or unrestricted “educational” funding from companies that directly profit from anticoagulant sales.

According to OpenSecrets and IRS Form 990 data, NBCA has received funding from pharmaceutical giants including Bristol Myers Squibb, Pfizer, and Janssen—the very manufacturers of Eliquis and Xarelto, the two most profitable clot-prevention drugs in the world. NATF lists corporate supporters that include Daiichi Sankyo, Anthos Therapeutics, and Bayer, all of which have a direct commercial stake in thrombosis treatment markets. Thrombosis UK’s financial reports show similar industry partnerships. None of this is illegal. It’s standard operating procedure in modern health advocacy.

The result is predictable: these groups push messaging that expands diagnosis and treatment pipelines but stops short of challenging the system that feeds them. Their campaigns tell patients to “know the signs” and “speak to your doctor,” but they rarely address structural issues—like the overprescription of direct oral anticoagulants (DOACs) or the lack of longitudinal data on lifelong bleeding risks. When conflicts of interest shape the information ecosystem, silence becomes strategy.

These organizations aren’t inherently corrupt; they’re trapped in a system where funding dictates visibility. The problem isn’t that they raise awareness—it’s that they can’t bite the hand that bankrolls them. So the conversation around blood clots stays carefully controlled: enough fear to fuel vigilance, enough vagueness to protect profits, and never enough transparency to make patients question who’s really writing the script.

The Medical Gatekeepers

Behind every clinical decision is a set of “evidence-based” guidelines written by organizations with deep financial ties to the pharmaceutical industry. The American Society of Hematology (ASH), American College of Cardiology (ACC), and International Society on Thrombosis and Haemostasis (ISTH) wield enormous power over what becomes standard care. Each regularly receives millions in corporate sponsorships, exhibitor fees, and “educational grants” from companies with active products in the anticoagulant and thrombosis markets.

ASH’s 2024 annual report lists Pfizer, Bristol Myers Squibb, Bayer, and Janssen among its top-tier sponsors, the same companies whose drugs dominate treatment algorithms. The ACC has accepted multimillion-dollar support packages from AstraZeneca, Novartis, and Boehringer Ingelheim, while publishing guidelines that directly affect prescription patterns for clot prevention and cardiovascular risk management. ISTH’s annual congresses feature “platinum” sponsorships from the same handful of pharmaceutical firms that control the global anticoagulant market. These relationships are built into the funding model of modern medicine.

Medical journals mirror the same dependency. Roughly 40% of revenue in leading clinical journals such as Blood, Circulation, and The New England Journal of Medicine comes from advertising, reprint sales, or supplements funded by industry. Those reprints, often of studies favorable to new drugs, are sold in bulk to pharmaceutical companies and distributed to clinicians as “educational material.” When a study’s publication can generate millions in reprint sales, neutrality becomes theoretical.

Even continuing medical education (CME), the system designed to keep physicians unbiased, has been hollowed out. The Accreditation Council for Continuing Medical Education (ACCME) reports that over 70% of CME funding now originates from commercial interests. That means the same corporations that make the drugs are paying to educate the doctors who prescribe them.

This is how “best practice” becomes a moving target nudged by sponsorship, codified by consensus committees stacked with consultants, and enforced by institutions that depend on the very industries they’re meant to regulate.

The Invisible Campaigns

Influence in medicine rarely looks like direct lobbying. It spreads through carefully constructed storytelling. Pharmaceutical marketing firms have turned patient testimony into one of their most effective tools. They create narratives that look authentic, but many are designed to generate emotion and urgency, which happen to be the two strongest triggers for behavior change.

Stories about young, athletic women suddenly developing blood clots circulate widely in news outlets and across social media. They appear organic, yet many trace back to public relations firms or marketing agencies under contract with drug manufacturers. These stories center on shock, fear, and speed. Each campaign reinforces the idea that immediate treatment is the only rational response, while avoiding harder conversations about prevention, misdiagnosis, and long-term safety.

A 2022 BMJ Open analysis found that more than 60 percent of online health campaigns related to major drug categories were financed or influenced by pharmaceutical companies, often without disclosure. Many of these campaigns operate through social media collaborations with health advocates who receive compensation through “educational partnerships” or “outreach grants.” The funding is buried in layers of intermediaries, leaving the final message appearing independent.

This isn’t deception in the traditional sense; it’s marketing that depends on credibility. Emotional stories reach audiences that conventional advertising cannot. They work because they appear human and unscripted. Over time, repetition builds belief—belief that the solution to clot risk begins and ends with a prescription.

What disappears in the process are the unprofitable questions. Why are clot incidents climbing? What policies allow known risks to remain underreported? How often are treatment guidelines updated without full outcome data? These questions lose airtime not by censorship but by saturation. The system doesn’t silence dissent—it buries it beneath the noise it pays to create.

Who Owns the Narrative

The conversation around blood clots has been built, edited, and financed by the same system that profits from its outcome. Lobbying isn’t limited to policy halls—it runs through clinical guidelines, medical education, public campaigns, and the so-called awareness movement itself. Pharmaceutical funding dictates which risks become headlines, which treatments are called “standard of care,” and which studies receive publication priority.

This isn’t a matter of individual corruption. It’s structural. The system rewards compliance with industry frameworks and punishes independence through lack of funding or visibility. Physicians who help write treatment guidelines believe they’re acting on evidence. Advocates who share sponsored campaigns believe they’re saving lives. Each actor plays their part sincerely, yet the end result remains the same: a health narrative filtered through corporate economics.

The truth is simple and hard to escape. The story of blood clots is no longer told by patients or practitioners, but curated by investors. Awareness has been converted into a commodity, and influence is now built into the infrastructure of medicine. Until funding and authorship are separated from profit, the conversation will continue to serve the market before it serves the public.